Expertise in
18
conditions

Dr. Marta Penas-Prado

Neurology
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 
Expertise in
18
conditions
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 

Overview

Marta Penas-Prado is a Neurologist practicing medicine in Cary, North Carolina.

Dr. Penas-Prado is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Astrocytoma, Glioblastoma, Brain Tumor, and Glioma.

She is actively involved in clinical research, co-authoring 101 peer reviewed articles and participating in 6 clinical trials.

Specialties

Neurology

Licenses

Psychiatry & Neurology in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

UT MD Anderson Cancer Center
210 Ashville Ave # 408, Cary, NC 27518

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Enrollment Status: Terminated
Publish Date: August 18, 2026
Intervention Type: Diagnostic test, Other, Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Phase 2 Study of VAL-083 Treatment for MGMT Unmethylated Bevacizumab-naïve Glioblastoma in the Adjuvant or Recurrent Setting
Phase 2 Study of VAL-083 Treatment for MGMT Unmethylated Bevacizumab-naïve Glioblastoma in the Adjuvant or Recurrent Setting
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drugs: VAL-083, Dianhydrogalactitol
Study Phase: Phase 2
A Phase I Lead-In to a 2x2x2 Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme
A Phase I Lead-In to a 2x2x2 Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme
Enrollment Status: Terminated
Publish Date: May 07, 2025
Intervention Type: Drug
Study Drugs: Mefloquine, Memantine Hydrochloride, Metformin Hydrochloride, Temozolomide
Study Phase: Phase 1
A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells for GBM Patients
A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells for GBM Patients
Enrollment Status: Completed
Publish Date: June 18, 2023
Intervention Type: Other, Drug, Biological, Procedure
Study Drugs: Autologous Cytomegalovirus-Specific Cytotoxic T Lymphocytes, Temozolomide
Study Phase: Phase 1/Phase 2
Phase II Study of Single-agent Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Phase II Study of Single-agent Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Enrollment Status: Completed
Publish Date: July 20, 2020
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients With High-Grade Gliomas
Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients With High-Grade Gliomas
Enrollment Status: Terminated
Publish Date: December 19, 2018
Intervention Type: Other, Drug
Study Phase: Not Applicable
View 5 Less Clinical Trials

101 Total Publications

Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.
Journal: medRxiv : the preprint server for health sciences
Published: July 03, 2026
Similar Doctors
Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nazanin Majd is a Neurologist practicing medicine in Cary, North Carolina. Dr. Majd is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Carlos Kamiya-Matsuoka is a Neurologist practicing medicine in Cary, North Carolina. Dr. Kamiya-Matsuoka is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioma, Glioblastoma, and Brain Tumor.

Expertise in
72
conditions
Expertise in
72
conditions
Referral required
Before you request

Duke Muscular Dystrophy Association (MDA) Clinic - Clinic 1L

40 Duke Medicine Cir, 
Durham, NC 
 (21.0 miles away)
919-681-5176
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vern Juel is a Neurologist practicing medicine in Durham, North Carolina. Dr. Juel is highly rated in 72 conditions, according to our data. His clinical expertise encompasses Myasthenia Gravis, Lambert-Eaton Syndrome, Inclusion Body Myositis, Meige Syndrome, and Thymectomy. Dr. Juel is board certified in American Board Of Psychiatry/Neurology, Clinical Neurophysiology , American Board Of Psychiatry/Neurology, Neuromuscular Medicine, and American Board Of Psychiatry/Neurology, Neurology . Dr. Juel is currently accepting new patients.

Frequently Asked Questions about Dr. Marta Penas-Prado

How do I make an appointment with Dr. Marta Penas-Prado?

You can book an appointment with Dr. Marta Penas-Prado by calling their office at 713-792-6161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Marta Penas-Prado a top-rated expert for Astrocytoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Marta Penas-Prado is classified as an Elite expert for Astrocytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Marta Penas-Prado specialize in?

While Dr. Marta Penas-Prado is a Neurology, they have specific expertise in Astrocytoma, Glioblastoma, and Brain Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Marta Penas-Prado participate in research or clinical trials?

Yes. Dr. Marta Penas-Prado has published 101 articles and abstracts on conditions like Astrocytoma. You can view a list of Dr. Marta Penas-Prado's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Penas-Prado's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile